74 results on '"van den Bent, Martin J."'
Search Results
2. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review
3. The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas
4. Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: relation to grade, histopathology and overall survival in the GLASS-NL cohort
5. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION
6. What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?
7. What is a glioblastoma?
8. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
9. Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation
10. Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
11. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas
12. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study
13. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors
14. Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
15. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas
16. MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas
17. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications
18. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
19. The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review
20. Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters
21. Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members
22. Hypermutated recurrences: Identifying the clinical relevance
23. Assessment of imaging biomarkers in the follow-up of brain metastases after SRS
24. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
25. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
26. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
27. Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial
28. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
29. Extent of radiological response does not reflect survival in primary central nervous system lymphoma
30. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials
31. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
32. Response to Letter to Editor
33. Determining medical decision-making capacity in brain tumor patients: why and how?
34. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial
35. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
36. Fast-growing oligodendrogliomas are aggressive tumors—the real life biomarker?
37. Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic
38. Quantification of leptomeningeal metastases from solid tumors remains a challenging issue
39. “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas
40. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases
41. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
42. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
43. Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups
44. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
45. Novel methods to diagnose leptomeningeal metastases in breast cancer
46. Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma
47. First results on the DCVax phase III trial: raising more questions than providing answers
48. Management of low-grade glioma: a systematic review and meta-analysis
49. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients withEGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
50. Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.